The AMY2A antibody targets the α-amylase 2A (AMY2A) enzyme, a pancreatic isoform of human α-amylase encoded by the *AMY2A* gene. AMY2A is primarily expressed in the pancreas and secreted into the digestive tract, where it catalyzes the hydrolysis of starch into sugars. This enzyme plays a critical role in carbohydrate metabolism and nutrient absorption. AMY2A antibodies are widely used in research to study pancreatic exocrine function, enzyme secretion mechanisms, and pathologies like pancreatitis, diabetes, or pancreatic cancer.
As a monoclonal or polyclonal antibody, AMY2A-specific reagents enable the detection and quantification of the enzyme in tissues (via immunohistochemistry) or biological fluids (via ELISA/Western blot). Elevated AMY2A levels in serum often indicate pancreatic injury, making it a diagnostic marker for acute pancreatitis. Conversely, reduced expression may link to pancreatic insufficiency or chronic conditions. Recent studies also explore its role in metabolic disorders and cancer progression, as aberrant amylase activity may influence tumor microenvironments.
Commercial AMY2A antibodies are typically validated for specificity against homologous isoforms (e.g., AMY1A or AMY2B) to avoid cross-reactivity. Ongoing research aims to refine its clinical utility, including therapeutic targeting and biomarker development.